- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Aerovate Therapeutics, Inc.: Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference | 1 | GlobeNewswire (USA) | ||
| 27.03. | Aerovate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 25.03. | Aerovate Therapeutics reports FY results | 1 | Seeking Alpha | ||
| 25.03. | Recap: Aerovate Therapeutics Q4 Earnings | 1 | Benzinga.com | ||
| 25.03. | Aerovate Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | Aerovate Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.03. | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights | 136 | GlobeNewswire (Europe) | Topline data expected in June 2024 from Phase 2b portion of the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Completed enrollment in the Phase... ► Artikel lesen | |
| 25.03. | Aerovate Therapeutics shares target lifted to $65 by Jefferies | 1 | Investing.com | ||
| 25.03. | US Aerovate Therapeutics, Kinetik Holdings, Motorola Solutions | 4 | Reuters | ||
| 20.03. | Aerovate Therapeutics exec sells over $181k in company stock | 1 | Investing.com | ||
| 20.03. | Aerovate Therapeutics CTO sells over $138k in company stock | 1 | Investing.com | ||
| 06.03. | Aerovate Therapeutics appoints new board chair amid trials | 1 | Investing.com | ||
| 06.03. | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair | 1 | GlobeNewswire (USA) | ||
| 08.01. | Aerovate Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 08.01. | Aerovate Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.11.23 | Aerovate Therapeutics, Inc.: Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial ... | 1 | GlobeNewswire (USA) | ||
| 20.11.23 | Aerovate Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | Aerovate Therapeutics GAAP EPS of -$0.71 misses by $0.02 | 1 | Seeking Alpha | ||
| 13.11.23 | Aerovate Therapeutics Inc reports results for the quarter ended in September - Earnings Summary | - | Reuters | ||
| 13.11.23 | Recap: Aerovate Therapeutics Q3 Earnings | 1 | Benzinga.com |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,140 | -1,29 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,350 | +3,21 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,680 | +1,71 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,780 | +2,96 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen AEROVATE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 21,750 Euro und damit +0,83 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
